Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82
oleh: Michael Lauseker, Markus Pfirrmann, Verena S. Hoffmann, Joerg Hasford
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2012-05-01 |
Deskripsi
No description available for this item.